Bell · Nature 2012 · preclinical animal and in vitro mechanistic study · n=?

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

Cited 1304 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal model (transgenic mice) and in vitro mechanistic research

PubMed 22622580 · doi:10.1038/nature11087 · record verified 2026-08-30

What was done

The authors investigated the mechanism by which APOE isoforms regulate cerebrovascular integrity using various mouse models, including human APOE transgenic mice (APOE2, APOE3, APOE4), Apoe-deficient mice, and mice with genetic ablation or inhibition of cyclophilin A (CypA). They examined blood-brain barrier (BBB) integrity, pericyte signaling pathways, cerebral microcirculation, and subsequent neuronal changes.

What was found

Expression of APOE4 or lack of Apoe, but not APOE2 and APOE3, led to BBB breakdown through activation of a proinflammatory CypA-nuclear factor-κB (NF-κB)-matrix metalloproteinase-9 (MMP-9) pathway in pericytes. This caused neuronal uptake of neurotoxic blood-derived proteins and reductions in microvascular density and cerebral blood flow. These vascular defects preceded neuronal dysfunction and initiated neurodegeneration. Astrocyte-secreted APOE3, but not APOE4, suppressed this pathway via a lipoprotein receptor. No quantitative values or sample sizes were reported in the abstract.

Why it matters

The findings define a pericyte-mediated molecular mechanism linking APOE4 to neurovascular breakdown and suggest cyclophilin A as a potential therapeutic target in APOE4-associated neurological disorders.

Limits

The study is preclinical, relying on transgenic mouse models and cellular assays, which may not fully translate to human pathology. The abstract reports no sample sizes or quantitative effect estimates.

Cited by